Aude Gandon Appointed Chief Digital & Marketing Officer, The Estée Lauder Companies
16.7.2025 12:45:00 CEST | Business Wire | Press Release
The Estée Lauder Companies Inc. (NYSE: EL) announced today that Aude Gandon has been appointed Chief Digital & Marketing Officer (CDMO), effective August 1, 2025. Ms. Gandon will report directly to Stéphane de La Faverie, President and Chief Executive Officer, and will join the company's Executive Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716106615/en/
Aude Gandon, Chief Digital & Marketing Officer (CDMO), The Estée Lauder Companies
In this newly created role, Ms. Gandon will lead the transformation of the company’s digital, marketing and media ecosystem, shaping end-to-end strategies across its powerful brand portfolio, and will oversee global digital commerce. Her appointment reflects the company’s commitment to evolving its consumer-centric approach and strengthening marketing as a commercial growth engine.
“Aude is an exceptional and accomplished global marketing leader with extensive experience transforming major consumer-facing businesses in the digital age,” said Stéphane de La Faverie. “Her deep expertise across all facets of marketing—from brand strategy and creative development to digital transformation and data analytics—will be instrumental as we continue to build stronger consumer connections. Her global perspective and proven track record of leading large-scale marketing, digital and media transformations make her the ideal leader for this critical role as we shape the future of prestige beauty."
As CDMO, Ms. Gandon will lead the company’s precision marketing, creative operations, consumer and category insights, regional store design and visual merchandising, omnichannel media strategy, and global consumer care; she will also oversee global digital commerce and partner closely with regional leadership to accelerate Online performance. This broad remit positions Ms. Gandon to elevate the consumer journey at every touchpoint to drive and amplify brand equity through creativity, precision and performance.
Ms. Gandon brings a unique blend of visionary leadership, digital expertise and creative acumen. She joins The Estée Lauder Companies from Nestlé, where she most recently served as Global Chief Marketing Officer and led the company’s digital transformation across 188 markets and more than 2,000 brands. She implemented new operating models, launched many global content studios, and developed strategic partnerships with major tech platforms, including Google, Meta, Amazon, and Netflix.
Prior to Nestlé, Ms. Gandon held leadership roles at Google, including Global Managing Director for Platform & Ecosystems, where she led integrated brand and creative strategies across five continents. Her earlier career includes senior roles in global advertising agencies such as Publicis Worldwide, McCann, and Leo Burnett, working with world-class beauty and luxury clients including L’Oréal, P&G Beauty, and LVMH.
“I am thrilled to join The Estée Lauder Companies, a company with an unparalleled portfolio of powerful brands and a strong heritage of innovation," said Aude Gandon. "As consumer behaviors continue to evolve, the opportunity to lead the digital and marketing transformation for a premier prestige beauty company is incredibly exciting. I look forward to partnering with the talented teams there to enhance our digital capabilities, deepen consumer connections, and drive growth across brands and channels.”
Ms. Gandon has previously served on the Board of Directors for CAPSUM, an innovative developer of skin care and makeup formulas, and is currently a board member of the World Federation of Advertisers, where she represents Europe and is chair of the Global CMO Committee. She also serves on the Amazon Ad Council and Meta Client Council.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement its strategy, including the Company’s profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
ELC-L
ELC-C
View source version on businesswire.com: https://www.businesswire.com/news/home/20250716106615/en/
Contacts
Media Relations:
Meridith Webster
mwebster@estee.com
Investor Relations:
Rainey Mancini
rmancini@estee.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom